Introduction
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder linked to an increased risk of metabolic abnormalities, including dyslipidemia, insulin resistance (IR), obesity, type II diabetes mellitus (T2DM), and hypertension.1,2,3,4 These comorbidities contribute to increased endothelial dysfunction and cardiovascular disease (CVD) risk.5,6 Both lean and obese women with PCOS also demonstrate impaired vascular structure and endothelial function, as evidenced by attenuated flow-mediated dilation and increased arterial intima-media thickness.7,8,9
Endothelial dysfunction is primarily caused by oxidative stress driven by an imbalance in reactive oxygen species (ROS). While reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOXs) are generally recognized as major contributors to the endothelial ROS pool, mitochondria-derived ROS serve as a critical and synergistic driver of oxidative damage, particularly under metabolic dysregulation such as hyperglycemia.10 As crucial integrators of cellular metabolism and environmental cues, mitochondria in endothelial cells (ECs) are central to vascular homeostasis. Chronic metabolic stressors, such as hyperglycemia, can induce endothelial mitochondrial dysfunction, manifesting as morphological fragmentation and excessive ROS production, which in turn promotes CVD progression.10,11,12 Mitochondrial dysfunction has also been reported in the ovary, oocyte, granulosa cell, uterus, placenta, and peripheral blood of women with PCOS.13 It is believed that abnormal mitochondrial ROS production and chronic inflammation are key factors in the pathogenesis of PCOS and are associated with hyperglycemia, polycystic ovarian morphology (PCOM), hyperandrogenism, and IR.13,14 While these links are recognized, the precise, cell-autonomous mechanisms by which PCOS predisposes the endothelium to damage, particularly under metabolic stress, remain largely undetermined.
Studying the biological function and pathogenesis of ECs in PCOS is challenging because it is nearly impossible to retrieve vascular ECs from patients. Patient-derived induced pluripotent stem cells (iPSCs) offer a unique opportunity to generate various specialized cell types, providing a powerful platform for studying disease pathogenesis and facilitating drug discovery.15,16 iPSCs have been successfully generated from women with PCOS in our previous studies16 as well as other publications, and subsequently re-differentiated into adipocytes,17 neural stem cells,18 and ovarian granulosa cells16 enabling direct investigation of underlying pathophysiology in PCOS under controlled conditions, particularly in tissues or cells that are otherwise inaccessible. In this study, we utilized iPSCs derived from three women with PCOS and three women without PCOS, which were then differentiated into ECs (PCOS iPSC-ECs and control iPSC-ECs).
Numerous studies have successfully used iPSC-ECs to investigate the pathogenesis of pulmonary arterial disease, hypertension, T2DM, cardiomyopathies, and calcified aortic valvular disease.19,20 This approach allowed us to isolate the innate susceptibility of PCOS endothelium. Specifically, we utilized high glucose (HG) as a clinically relevant metabolic stressor to determine whether PCOS iPSC-ECs harbor latent mitochondrial defects that are unmasked under hyperglycemic conditions, thereby predisposing patients to endothelial dysfunction.
Additionally, several circulating markers of oxidative stress, endothelial damage, and inflammation, including malondialdehyde, high-sensitivity C-reactive protein, soluble platelet/EC adhesion molecule-1, and myeloperoxidase (MPO), have been reported to be elevated in PCOS women.7,21,22,23 MPO, in particular, is known to promote mitochondrial dysfunction and impair endothelium-dependent relaxation by reducing nitric oxide (NO) bioavailability in ECs.24 In T2DM, elevated MPO is independently associated with increased cardiovascular events beyond traditional risk factors.25 Together, these findings suggest that chronic hyperglycemia promotes systemic inflammation and oxidative stress, leading to increased MPO activity, which then further exacerbates vascular injury. Although IR is a hallmark of PCOS, hyperglycemia acts as a potent driver of endothelial inflammation and oxidative stress. However, the precise mechanism by which MPO contributes to EC dysfunction and altered mitochondrial function in PCOS remains unclear.
Therefore, in this study, we assessed serum MPO levels in women with PCOS and age- and body mass index (BMI)-matched controls, in relation to various hormonal and metabolic phenotypes. In addition, we hypothesized that aberrant MPO expression serves as a potential intracellular mediator that exacerbates mitochondrial dysfunction under metabolic stress. We used an iPSC-EC model to investigate the potential contributing factors, such as hyperglycemia, that regulate MPO expression and mitochondrial function.
Through these approaches, we aim to elucidate whether the increased susceptibility of PCOS endothelium to hyperglycemia and higher risk of CVD in women with PCOS may be attributed to dysregulated mitochondrial function and aberrant MPO activity.
Results
HG impaired angiogenesis in PCOS iPSC-ECs
The biological and mitochondrial functions of the iPSC-ECs under HG conditions were evaluated. A 24-h exposure to HG (30 mM) resulted in a marked and significant impairment of capillary-like tube formation in PCOS iPSC-ECs, relative to normal glucose (NG) (5.5 mM) conditions (Figure 1). In contrast, the tube-forming capacity of control iPSC-ECs remained unaffected under identical HG conditions.
This impaired angiogenic capacity was consistently observed across all individual PCOS iPSC-EC lines (Figure S1). The 30 mM glucose concentration was selected based on established in vitro protocols to stimulate endothelial hyperglycemic states.26,27Figure 1Hyperglycemia impairs angiogenic capacity in PCOS iPSC-ECs(A and B) (A) Representative images and (B) quantification of relative total tube length in control and PCOS iPSC-ECs exposed to NG (5.5 mM) or HG (30 mM) for 24 h. Data are presented as mean ± SD, with individual data points shown.
Grouped data from the control (N4, N5, and N8) and PCOS (P4, P5, and P7) groups were compared (n = 9 independent data points; 3 independent experiments × 3 distinct iPSC lines per group) using two-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. NG. Scale bars, 100 μm.
Abbreviations: iPSC-ECs, induced pluripotent stem cell-derived endothelial cells; NG, normal glucose; HG, high glucose. See also Figure S1.
HG disrupted mitochondrial morphology and increased mitochondrial ROS production in PCOS iPSC-ECs
The mitochondrial morphology of PCOS and control iPSC-ECs was assessed by confocal staining with the outer mitochondrial membrane protein TOM20 after 24-h incubation with HG or NG (Figure 2A). In the NG medium, both PCOS and control iPSC-ECs exhibited a highly interconnected, tubular mitochondrial network. In contrast, PCOS iPSC-ECs grown in HG medium for 24 h showed significant mitochondrial fragmentation, whereas control iPSC-ECs maintained mitochondrial integrity under the same conditions.
Quantitative analysis of mitochondrial organization using the Mitochondrial Network Analysis (MiNA) demonstrated a reduction in mitochondrial footprint, mean branch length, and mean number of branches per network in HG-treated PCOS iPSC-ECs (Figure 2B).Figure 2Hyperglycemia induces mitochondrial dysfunction in PCOS iPSC-ECs(A) Representative confocal microscopy images of mitochondrial morphology visualized by TOM20 staining (green) and nuclei (blue). Scale bars, 5 μm.(B) Quantitative analysis of mitochondrial network parameters, including mitochondrial footprint, mean branch length, and mean number of branches per network using the MiNA toolset.(C and D) (C) Representative western blot images and (D) densitometric quantification of mitochondrial fusion (mitofusin-1 [MFN1], mitofusin-2 [MFN2], and optic atrophy 1 [OPA1]) and fission (dynamin-related protein 1 [DRP1] and mitochondrial fission 1 protein [FIS1]) proteins. Protein levels were normalized to β-actin.(E) Quantification of mitochondrial ROS production measured by MitoSOX™ Red fluorescence intensity.
IL-1β and NO donor DETA NONOate (indicated as NONOate in the figure) were included as positive and negative controls, respectively.Data are presented as mean ± SD, with individual data points shown. Grouped data from the control (N4, N5, and N8) and PCOS (P4, P5, and P7) groups were compared (n = 9 independent data points; 3 independent experiments × 3 distinct iPSC lines per group) using two-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. NG.
Abbreviations: iPSC-ECs, induced pluripotent stem cell-derived endothelial cells; NG, normal glucose; HG, high glucose; ROS, reactive oxygen species; MFN, mitofusin; OPA1, optic atrophy 1; DRP1, dynamin-related protein 1; FIS1, mitochondrial fission 1 protein; IL-1β, interleukin 1 beta; DETA NONOate, diethylenetriamine NONOate. See also Figures S2 and S3.
The expression of mitochondrial dynamics-related proteins was measured by western blot in HG and NG media (Figure 2C). Mitochondrial fusion is regulated by mitofusin-1 (MFN1), mitofusin-2 (MFN2), and optic atrophy 1 (OPA1), while mitochondrial fission is regulated by dynamin-related protein 1 (DRP1) and mitochondrial fission 1 protein (FIS1). HG induced MFN1, MFN2, OPA1, and DRP1 expression in control iPSC-ECs (Figures 2C and 2D).
However, protein levels of MFN1, MFN2, and OPA1 showed no significant change after HG incubation in PCOS iPSC-ECs. Conversely, protein levels of DRP1 and FIS1 were increased in PCOS iPSC-ECs under the same conditions (Figures 2C and 2D). Original western blot images have been provided (Figure S3A).
Mitochondrial-specific ROS production was measured using the MitoSOX Red indicator. PCOS and control iPSC-ECs were cultured on 96-well plates with either HG or NG medium for 24 h. Additional conditions treated with interleukin 1 beta (IL-1β) were included as positive controls.
As a negative control, cells were treated with NO donor diethylenetriamine NONOate (DETA NONOate). Mitochondrial ROS accumulation was observed in PCOS iPSC-ECs following HG treatment, but not in control iPSC-ECs (Figure 2E). Analysis of individual cell lines confirmed consistent trends in morphological disruption and increased ROS, although compensatory fusion protein responses exhibited biological variability among the PCOS lines (Figures S2A–S2C).
Collectively, these findings indicated that HG altered mitochondrial morphology, disrupted mitochondrial network dynamics, and increased mitochondrial ROS production in PCOS iPSC-ECs.
HG impaired mitochondrial bioenergetic function in PCOS iPSC-ECs
To further analyze mitochondrial respiratory activity, we measured the oxygen consumption rates (OCRs) using the Seahorse XFe24 analyzer. After a 24-h incubation of PCOS and control iPSC-ECs in HG or NG medium, we assessed basal OCR and OCR in response to consecutive injections of oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and rotenone/antimycin (Figure 3A). HG significantly reduced basal respiration, maximal respiration, ATP production, and spare respiratory capacity in PCOS iPSC-ECs, but not in control iPSC-ECs (Figure 3B).
Individual line-by-line analysis showed a consistent downward trend in bioenergetic parameters of HG-treated PCOS iPSC-ECs (Figure S4). Taken together, these data suggested that 24-h HG incubation led to mitochondrial fragmentation and a decrease in mitochondrial metabolic capacity in PCOS iPSC-ECs.Figure 3High glucose compromises mitochondrial bioenergetics in PCOS iPSC-ECs(A) Mitochondrial respiration profiles of control (N4, N5, and N8) and PCOS (P4, P5, and P7) iPSC-ECs measured by the Seahorse XFe24 analyzer. Oxygen consumption rate (OCR) was monitored at baseline and following sequential injections of oligomycin (ATP synthase inhibitor), FCCP (uncoupler), and rotenone/antimycin (complex I/III inhibitors).(B) Quantification of basal respiration, maximal respiration, ATP production, and spare respiratory capacity derived from the OCR traces.
Values are normalized to the NG condition for each cell line.Data are presented as mean ± SD, with individual data points shown. Grouped data from control (N4, N5, and N8) and PCOS (P4, P5, and P7) groups were compared (n = 9 independent data points; 3 independent experiments × 3 distinct iPSC lines per group) using two-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs. NG.
Abbreviations: iPSC-ECs, induced pluripotent stem cell-derived endothelial cells; NG, normal glucose; HG, high glucose. See also Figure S4.
HG induced MPO gene and protein expression in PCOS iPSC-ECs
Given that elevated MPO promotes endothelial mitochondrial dysfunction and serves as a biomarker of inflammation and oxidative stress associated with CVD,23,24 and has previously been reported to be elevated in women with PCOS,22 we investigated whether iPSC-ECs express the MPO gene and protein under HG and NG medium conditions. Real-time RT-qPCR analysis revealed detectable MPO mRNA expression (cycle threshold [CT] values <35) in all PCOS and control iPSC-ECs. After 24 h of HG induction, MPO mRNA expression was significantly upregulated in PCOS iPSC-ECs relative to NG conditions (Figure 4A).
This was corroborated at the protein level. Western blot analysis revealed the presence of autocatalytic MPO fragments (43–47 kDa) in both PCOS and control iPSC-ECs (Figure 4B). HG exposure increased MPO protein levels in PCOS iPSC-ECs.
Furthermore, treatment with aminobenzoic acid hydrazide (4-ABAH), a potent inhibitor of MPO, restored angiogenic capacity and reduced mitochondrial ROS in HG-treated PCOS iPSC-ECs, while mannitol treatment was included as an osmotic control (Figures 4C and 4D). Analysis of individual cell lines confirmed consistent trends in both HG-induced MPO upregulation and the subsequent functional recovery following 4-ABAH treatment across the PCOS iPSC-ECs (Figures S5A–S5E). Original western blot images are provided in Figure S3B.
Collectively, these findings indicate that HG triggers MPO upregulation in PCOS iPSC-ECs, which potentially contributes to the observed mitochondrial oxidative stress and angiogenic impairment.Figure 4Hyperglycemia-induced myeloperoxidase upregulation and the protective effects of MPO inhibition in PCOS iPSC-ECs(A and B) (A) Relative MPO mRNA expression and (B) representative western blot images with quantification of MPO protein levels in control and PCOS iPSC-ECs incubated in NG or HG for 24 h. Protein levels were normalized to β-actin.(C) Quantification of relative total tube length in control and PCOS iPSC-ECs exposed to NG, mannitol (24.5 mM; osmotic control), HG, or HG plus the MPO inhibitor aminobenzoic acid hydrazide (4-ABAH) for 24 h.(D) Quantification of mitochondrial ROS production, measured by MitoSOX™ Red fluorescence intensity, across the corresponding treatment groups.All data are presented as mean ± SD, with individual data points shown. Grouped data from control (N4, N5, and N8) and PCOS (P4, P5, and P7) groups were compared (n = 9 independent data points; 3 independent experiments × 3 distinct iPSC lines per group) using two-way ANOVA test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 vs.
NG in (A) and (B), or between the indicated conditions in (C) and (D). Abbreviations: MPO, myeloperoxidase; iPSC-ECs, induced pluripotent stem cell-derived endothelial cells; NG, normal glucose; HG, high glucose. See also Figure S5.
Clinical characteristics of subjects, measurements of circulating MPO, and correlation studies
In order to strengthen translational relevance, a clinical cohort was incorporated to determine whether the molecular signatures identified in iPSC-derived endothelial models are recapitulated in vivo. Serum MPO concentrations were quantified in 22 women with PCOS and 20 age- and BMI-matched control women without PCOS. All participants in the PCOS cohort were treatment-naïve at the time of blood sampling.
Significantly higher MPO levels were observed in the PCOS group, accompanied by alterations in other metabolic and endocrinological parameters (Table 1). Furthermore, the PCOS cohort exhibited a significantly higher prevalence of metabolic comorbidities, including hypertension, pre-diabetes, and IR, compared to the control group. Pearson’s correlation analysis demonstrated a significant positive correlation between serum MPO levels and diastolic blood pressure (DBP) (r = 0.445 and p = 0.038), glucose levels (r = 0.43 and p = 0.046), as well as low-density lipoprotein (LDL) cholesterol levels (r = 0.048 and p = 0.033) in women with PCOS, whereas these relationships were not observed in the control group (Figures 5A, 5C, and 5E).
In contrast, serum MPO concentrations were not significantly correlated with systolic blood pressure (SBP) or with serum levels of insulin, high-density lipoprotein (HDL), testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH) or estradiol (E2) in either group (Figures 5B, 5D, 5F, and S6). To determine whether the association between MPO and glucose levels is independent of other metabolic factors, multivariable linear regression analyses were performed to evaluate their relationship after adjusting for potential confounders (Table S1). The positive association between MPO and glucose remained significant after simultaneously adjusting for both BMI and insulin (β = 16.02 and p = 0.0497) in the PCOS group.
However, this association was attenuated and lost statistical significance upon adjustment for blood pressure parameters (DBP or SBP). Collectively, these clinical observations highlight a significant association between circulating MPO and hyperglycemic status in women with PCOS, suggesting that systemic MPO levels are closely related to metabolic dysregulation and vascular health.Table 1Clinical and biochemical characteristics of women with PCOS and controlsControl (n = 20)PCOS (n = 22)p valueAnthropometric profileAge (year)28.4 ± 4.126.8 ± 4.20.240Menstrual interval (day)30.2 ± 3.0138.4 ± 102.3<0.001∗BH (cm)159.7 ± 4.7159.9 ± 5.60.919BW (kg)74.5 ± 8.178.1 ± 9.00.171BMI (kg/m2)29.2 ± 2.730.5 ± 2.60.110WC (cm)94.1 ± 8.199.0 ± 7.30.048∗HC (cm)103.9 ± 7.7104.9 ± 5.30.613SBP (mmHg)105.7 ± 10.3120.3 ± 15.90.001∗DBP (mmHg)73.4 ± 8.381.8 ± 12.30.013∗HR (bpm)71.8 ± 8.177.8 ± 11.80.061Endocrinological profilesUterus volume (cm3)75.5 ± 45.356.2 ± 20.50.093OV (cm3)6.8 ± 2.410.1 ± 4.00.003∗FNPO (count)9.1 ± 9.017.9 ± 11.40.036∗SHBG (nmol/L)40.7 ± 15.917.2 ± 8.0<0.001∗Testosterone (ng/mL)0.5 ± 0.20.6 ± 0.10.027∗FSH (mIU/mL)6.9 ± 1.46.3 ± 1.60.199LH (mIU/mL)3.9 ± 1.37.1 ± 3.8<0.001∗E2 (pg/mL)38.0 ± 18.847.1 ± 29.20.234P4 (ng/mL)0.5 ± 0.20.7 ± 1.70.559Prolactin (ng/mL)12.7 ± 6.211.1 ± 4.60.355TSH (uIU/mL)1.6 ± 0.81.8 ± 0.90.410DHEAS (ug/dL)248.2 ± 115.0383.8 ± 167.30.004∗FAI (%)4.7 ± 2.214.7 ± 7.8<0.001∗AMH (ng/mL)3.8 ± 2.39.6 ± 4.9<0.001∗Metabolic profilesInsulin (uIU/mL)8.4 ± 3.016.4 ± 7.4<0.001∗Glucose (mg/dL)83.6 ± 5.193.2 ± 12.70.003∗HOMA-IR1.7 ± 0.73.7 ± 1.6<0.001∗T-CHO (mg/dL)179.4 ± 26.2202.0 ± 31.20.017∗LDL (mg/dL)110.4 ± 23.7132.9 ± 28.70.013∗HDL (mg/dL)53.8 ± 9.750.3 ± 12.40.333TG (mg/dL)89.4 ± 33.1138.8 ± 69.90.008∗AST (U/L)14.9 ± 5.033.6 ± 34.10.025∗ALT (U/L)11.3 ± 5.940.9 ± 44.40.006∗Comorbidities n (%)Hypertension2 (10)11 (50)0.014∗Dyslipidemiaa12 (63.2)16 (76.2)0.580Diabetes03 (13.6)0.265Pre-diabetesb010 (50)0.001∗IR2 (10)17 (77.3)<0.001∗Others001Concurrent medication001MPO (ng/mL)393.9 ± 231.2668.6 ± 467.70.020∗Data represent mean ± SD or n (%). p values were determined by the unpaired t test or chi-squared test. ∗p < 0.05 was considered statistically significant. Abbreviations: BH, body height; BW, body weight; BMI, body mass index; WC, waist circumference; HC, hip circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; OV, ovarian volume; FNPO, follicle number per ovary; SHBG, sex hormone binding globulin; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; P4, progesterone; TSH, thyroid-stimulating hormone; DHEAS, dehydroepiandrosterone; FAI, free androgen index; AMH, anti-Müllerian hormone; HOMA-IR, homeostatic model assessment for insulin resistance; T-CHO, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; IR, insulin resistance; TG, triglyceride; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MPO, myeloperoxidase.
Bold entries indicate subheadings for categorization and highlight the key marker MPO.Dyslipidemia is defined as T-CHO ≥200, or TG ≥150, or LDL ≥130, or HDL <50.28Hypertension is defined as SBP ≥130 mmHg or DBP ≥90 mmHg.29Diabetes is defined as AC sugar >126, or 2-h OGTT >200.30Pre-diabetes is defined as AC sugar: 100–125, or 2-h OGTT 140–199.30Insulin resistance is defined as HOMA-IR >2.5.31aMissing data exist for 1 case in the control group and 1 case in the PCOS group.bMissing data exist for 2 cases in the PCOS group.Figure 5Relationships between serum myeloperoxidase levels and phenotypic variables(A–F) Scatterplots illustrating the correlations between serum MPO concentrations and (A) diastolic blood pressure (DBP), (B) systolic blood pressure (SBP), (C) serum glucose levels, (D) insulin (E) low-density lipoprotein (LDL), and (F) high-density lipoprotein (HDL). The study cohort included women with PCOS (pink circles, n = 22) and age- and BMI-matched control (green circles, n = 20). Linear regression lines are plotted for each group.
Pearson correlation coefficients (r) and p values are indicated next to the corresponding regression lines. The interaction term p value (bottom of each image) was derived from multiple linear regression analysis to assess whether the association between MPO and the indicated clinical variable differs significantly between the PCOS and control groups. Statistical analyses were performed using R software and R Studio.
Multiple linear regression with a group-by-MPO interaction term was used to analyze clinical data. Correlation analysis was used to determine the correlation between MPO levels and metabolic and clinical characteristics. ∗p < 0.05 was considered statistically significant. See also Figure S6.
Discussion
Endothelial dysfunction represents a central contributor to the heightened cardiometabolic risk in women with PCOS, yet the mechanistic basis underlying this vascular vulnerability remains poorly understood. In this study, we utilized patient-specific PCOS iPSC-ECs to uncover a latent cellular vulnerability. We found that PCOS iPSC-ECs exhibit a reduced resilience when challenged with hyperglycemia.
A 24-h exposure to HG markedly impaired angiogenic capacity, disrupted mitochondrial network organization, reduced mitochondrial metabolic activity, and increased mitochondrial ROS production in PCOS iPSC-ECs, whereas control iPSC-ECs remained largely resilient under identical conditions. These findings indicate that PCOS endothelium is more vulnerable to hyperglycemic injury, consistent with prior reports demonstrating HG-induced mitochondrial fragmentation and vascular dysfunction in diabetic ECs, animal models, and human subjects.1,12,32 While acute (6-h) HG exposure enhances mitochondrial ROS, fission, and metabolic impairment in human aortic ECs (HAECs),11 we did not observe a detectable change in mitochondrial respiration at this early time point in our iPSC-ECs (data not shown).
Our data further suggest an impairment of adaptive mitochondrial dynamics in PCOS endothelium. While control iPSC-ECs mounted a compensatory upregulation of fusion proteins (MFN1, MFN2, and OPA1) to counteract hyperglycemic stress, a known survival mechanism to dilute damaged mitochondrial DNA,12 PCOS iPSC-ECs failed to initiate this protective response. This suggests that the pathology in PCOS involves not just a susceptibility to injury, but an impaired adaptive response to cellular stress.
Furthermore, this mitochondrial dysfunction is linked to oxidative and inflammatory networks. It is well-established that HG microenvironments and metabolic stress activate the NOX pathway, which serves as an upstream driver of oxidative stress in ECs.33,34 Consistent with these mechanisms, our PCOS iPSC-EC model exhibits downstream pathological consequences, including mitochondrial dysfunction and enhanced endothelial activation (Figure S7). Specifically, the marked upregulation of the adhesion molecules vascular cell adhesion molecule 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1) under HG conditions reflects the activation of inflammatory signaling associated with oxidative stress and may contribute to the impaired angiogenic capacity observed in our model.
Since iPSC reprogramming theoretically resets environmental epigenetic marks, the persistence of these mitochondrial defects and aberrant MPO expression in PCOS-derived ECs raises the possibility that these traits may reflect genetic susceptibility or persistent epigenetic memory. These findings support the concept that vascular dysfunction in PCOS is not merely a secondary consequence of systemic hormonal imbalances, but stems from a stable cell-autonomous phenotype.35 Collectively, these findings highlight that ECs from women with PCOS exhibit a cell-autonomous mitochondrial vulnerability that becomes unmasked under hyperglycemic stress, providing a mechanistic framework linking metabolic dysregulation in PCOS to downstream cardiovascular risk.
Traditionally, MPO is known as a heme peroxidase primarily synthesized by neutrophils, monocytes, and tissue macrophages under pathological conditions, and in vivo endothelial dysfunction is classically attributed to these myeloid-derived sources.24 Our clinical data revealed that women with PCOS had significantly higher serum MPO levels than control women. This elevation likely reflects the chronic inflammatory and oxidative stress milieu characteristic of PCOS. Crucially, we distinguish these circulating levels, which primarily originate from activated neutrophils and serve as systemic biomarkers, from the localized, intracellular MPO expression observed in our iPSC-EC model.
To further support this distinction, MPO was undetectable in the culture supernatant of both PCOS and control iPSC-ECs in our study (data not shown), consistent with its intracellular, rather than secreted, localization in these ECs.
Previous studies have shown that plasma MPO correlates with ROS generation, leukocyte-endothelium interaction, endothelial adhesion molecules (E-selectin, ICAM-1, and VCAM-1), and pro-inflammatory cytokines (interleukin 6 [IL-6], tumor necrosis factor alpha [TNF-α]) particularly in PCOS women with IR.9 However, in contrast to those findings, our study did not find a correlation between serum MPO and insulin levels. To further distinguish these metabolic effects, our multivariable regression analyses demonstrated that the positive association between MPO and glucose in PCOS group remained significant even after adjusting for BMI and insulin level. Although the presence of metabolic comorbidities may potentially influence circulating MPO levels, these clinical observations remain consistent with the proposed hypothesis that hyperglycemic stress serves as a potent trigger driving MPO elevation and promoting endothelial dysfunction in women with PCOS, independent of the established role of IR.
This interpretation is consistent with external evidence demonstrating MPO’s capacity to exacerbate endothelial dysfunction in high-glucose-incubated rat aortas and carotid arteries from hyperglycemic rats.36
Our in vitro data showed that PCOS iPSC-ECs respond to HG by altering MPO expression at both mRNA and protein levels. Treatment with the MPO inhibitor 4-ABAH attenuated the HG-induced increase in mitochondrial ROS and restored impaired angiogenesis (tube formation) in PCOS iPSC-ECs. This suggests that endogenous MPO in ECs may play distinct, potentially intracellular, roles in cellular damage responses, contributing to the observed mitochondrial dysfunction under hyperglycemic conditions.
Previous research has shown that H2O2 induces MPO expression in endocardial ECs (EECs) from patients with chronic heart failure (CHF) and in human umbilical vein ECs (HUVECs).37
MPO has similarly been detected in endothelial colony-forming cells (ECFCs) from both coronary artery disease (CAD) patients and non-CAD patients, where its primary nuclear localization is atypical compared to its conventional secretion from neutrophil and monocyte granules.38 The expression of MPO in CAD ECFCs was associated with increased mitochondrial dysfunction, while extracellular MPO expression remained minimal.38
Importantly, by integrating clinical cohort data with iPSC-derived endothelial mechanistic experiments, our study provides convergent evidence that elevated MPO is not only a measurable clinical biomarker but also as a potential contributor to mitochondrial vulnerability. These findings highlight a possible link between cellular mechanisms and the elevated cardiovascular risk observed in PCOS.
In conclusion, the integration of clinical phenotyping and patient-derived iPSC modeling supports a working model for a potential pathogenic mechanism in PCOS: an endogenous metabolic-oxidative vulnerability. Our data propose that the endothelium harbors a latent inherent mitochondrial defect that sensitizes the cell to the metabolic stress of hyperglycemia. This susceptibility may contribute to impaired angiogenesis and mitochondrial dysfunction, a process that is associated with, and potentially modulated by, dysregulated MPO activity.
While our pharmacological inhibition data suggest a contributory role for MPO in these cellular damage responses, further mechanistic studies are required to definitively establish direct causality.
Limitations of the study
Several considerations should be noted when interpreting these findings. First, the number of patient-derived iPSC lines was limited, owing to the inherent technical complexity of iPSC-EC differentiation and maintenance. However, all three PCOS iPSCs were derived from patients with classical full-blown phenotypes.
Second, the clinical cohort size was not large enough to permit subgroup analyses based on the four PCOS phenotypes (A–D) defined by the Rotterdam criteria and further characterized in our previous clinical studies.39,40 Despite these limitations, the findings were consistent across the three independent PCOS iPSC lines and multiple complementary assays. In addition, parallel elevations in circulating MPO were observed in the clinical cohort. Third, while our pharmacological inhibition data highlight a functional role for MPO, definitive proof of a direct mechanistic link is limited by the lack of genetic gain- and loss-of-function models.
Future studies incorporating targeted genetic manipulation, direct MPO enzymatic activity assays, and high-resolution subcellular imaging are required to fully elucidate the intracellular MPO-mitochondrial axis. Furthermore, the application of 30 mM glucose for 24 h represents an acute and severe HG challenge rather than chronic exposure, and therefore may not fully recapitulate the clinical setting. Lastly, due to clinical limitations and the restricted availability of patient-derived primary ECs, MPO was quantified only in serum, precluding direct intracellular measurements within resident or circulating endothelial progenitor cells.
Further mechanistic and longitudinal studies are required to determine how these pathways interact and whether MPO-related signaling contributes to long-term cardiovascular risk in women with PCOS.
Resource availability
Lead contact
Requests for further information, resources, and reagents should be directed to and will be fulfilled by the lead contact, Hong-Nerng Ho (hnho@tmu.edu.tw).
Materials availability
This study did not generate new unique reagents.
Data and code availability
•All data generated or analyzed during this study are included in the published article and supplemental information.•No code was generated.•Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
Acknowledgments
We would like to acknowledge the service provided by the Immune Research Core of Department of Medical Research at National Taiwan University Hospital for technical support with Seahorse XF analysis. We also thank the imaging core at the First Core Labs, National Taiwan University College of Medicine, for their assistance with confocal microscopy image acquisition and analysis. This work was supported by the 10.13039/100020595National Science and Technology Council of Taiwan (113-2314-B-038-002 [H.-N.H.] and 10.13039/100020595NSTC112-2314-B-002-162-MY3 [C.-C.H.]); and the 10.13039/501100005762National Taiwan University Hospital (NTUH 113-E0002 [M.-J.C.], 114-E0006 [M.-J.C.], and 115-E0006 [M.-J.C.]).
Author contributions
C.-E.W., conceptualization, methodology, investigation, formal analysis, writing – original draft, and writing – review and editing; C.-C.H., conceptualization, methodology, funding acquisition, and writing – review and editing; T.-H.C., investigation; C.-C.T., investigation; I.-J.Y., formal analysis; Y.-Y.C., formal analysis; M.-J.C., conceptualization, methodology, resources, funding acquisition, supervision, and writing – review and editing; H.-N.H., conceptualization, methodology, funding acquisition, supervision, and writing – review and editing.
Declaration of interests
The authors declare no competing interests.
Declaration of generative AI and AI-assisted technologies in the manuscript preparation process
The authors declare that no generative AI or AI-assisted technologies were used in the writing, data analysis, or image generation for this study.
STAR★Methods
Key resources table
REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesMouse monoclonal anti-TOM20 (F-10)Santa Cruz BiotechnologyCat#sc-17764; RRID: AB_628381Rabbit monoclonal anti-MFN-1 (D6E2S)Cell Signaling TechnologyCat#14739; RRID: AB_2744531Rabbit monoclonal anti-MFN-2 (D1E9)Cell Signaling TechnologyCat#11925; RRID: AB_2750893Rabbit monoclonal anti-OPA1 (D7C1A)Cell Signaling TechnologyCat#67589; RRID: AB_2799728Rabbit monoclonal anti-DRP1 (D6C7)Cell SignalingCat#8570; RRID: AB_10950498Mouse monoclonal anti-FIS1 (B-5)Santa Cruz BiotechnologyCat#sc-376447; RRID: AB_11149382Rabbit monoclonal anti-MPO (E1E7I)Cell Signaling TechnologyCat#14569; RRID: AB_2798516Goat polyclonal anti-β-ActinAbcamCat#ab8229; RRID: AB_306374Biological samplesHuman serum: Control womenNational Taiwan University HospitalN/AHuman serum: PCOS womenNational Taiwan University HospitalN/AChemicals, peptides, and recombinant proteinsPrimate ES Cell MediumREPROCELLCat#RCHEMD001STEMdiff APEL MediumSTEMCELL TechnologiesCat#05275Endothelial cell growth medium MV2PromoCellCat#c-22022Matrigel hESC-Qualified matrixCorningCat#354277Matrigel growth factor-reduced Basement membrane matrixCorningCat#354230AccutaseThermo Fisher ScientificCat#00–4555–56Recombinant Human VEGF 165R&D systemsCat#293-VERecombinant Human bFGFR&D systemsCat#3718-FBRecombinant Human BMP-4R&D systemsCat#314-BPCHIR 99021Tocris BioscienceCat# 4423Recombinant Human IL-1βR&D systemsCat#201-LBDETA NONOateSigma-AldrichCat#D184Halt Protease and Phosphatase inhibitor cocktail (100×)Thermo Fisher ScientificCat#78440SuperSignal West Pico PLUS Chemiluminescent Substrate (ECL)Thermo Fisher ScientificCat#34580RIPA (10×)MilliporeCat#20–188D-GlucoseSigma-AldrichCat# G7021D-MannitolSigma-AldrichCat# M41254-Aminobenzoic Acid hydrazideCayman ChemicalCat#14845Critical commercial assaysMitoSOXTM Mitochondrial Superoxide IndicatorsThermo Fisher ScientificCat#M36005Human Myeloperoxidase Quantikine ELISA kitR&D systemsCat#DMYE00BcDNA synthesis kit for RT-qPCRThermo Fisher ScientificCat#K1641Fast SYBR Green master mixThermo Fisher ScientificCat#4385612Seahorse XF Cell Mito Stress Test KitAgilent TechnologiesCat#103015–100Experimental models: Cell linesHuman: iPSC line N4: ControlThis paperN/AHuman: iPSC line N5: ControlThis paperN/AHuman: iPSC line N8: ControlThis paperN/AHuman: iPSC line P4: PCOSThis paperN/AHuman: iPSC line P5: PCOSThis paperN/AHuman: iPSC line P7: PCOSWu et al.37N/AMouse: CF1 iMEF (Irradiated): Wild-typeiXcells BiotechnologiesCat#10MU-001OligonucleotidesPrimer: MPO Forward: 5′-CCGGGATGGTGATCGGTTTT-3′This paperN/APrimer: MPO Reverse: 5′-CAGATGATCCGGGGCAATGA-3′This paperN/APrimer: VCAM1 Forward: 5′-TCAGATTGGAGACTCAGTCATGT-3′This paperN/APrimer: VCAM1 Reverse: 5′-ACTCCTCACCTTCCCGCTC-3′This paperN/APrimer: ICAM1 Forward: 5′-ATAACCGCCAGCGGAAGATCAAGA-3′This paperN/APrimer: ICAM1 Reverse: 5′-CGTGGCTTGTGTGTTCGGTTTCAT-3′This paperN/APrimer: eEF1α1 Forward: 5′-GCCAGAACACAGGTGTCGTGAAAAC-3′This paperN/APrimer: eEF1α1 Reverse: 5′-CAGATGGCCAGTAGTGGTGGACTTG-3′This paperN/ASoftware and algorithmsGraphPad Prism 10GraphPad SoftwareRRID: SCR_002798; (https://www.graphpad.com/)Fiji (ImageJ)NIHRRID: SCR_002285; (https://ImageJ.net/software/fiji/)Seahorse Wave Desktop Software (Version 2.2)Agilent Technologieshttps://agilent.com/R (version 4.3.3) and RStudio (version 2024.04.2)R Core Team (R)/Posit Software, PBC (RStudio)https://www.r-project.org/ggplot2 (version 3.5.1)Posithttps://github.com/tidyverse/ggplot2
Experimental model and study participant details
Human iPSC culture and endothelial differentiation
Three human control iPSC lines (N4, N5, N8) and three PCOS iPSC lines (P4, P5, P7) were used in this study. The generation of the P7 line (NTUHi006-A) has been previously described.41 All other iPSC lines were established using the same standardized protocols. Briefly, all iPSC lines were derived from peripheral blood mononuclear cells (PBMCs) using Sendai virus-based reprogramming.
To ensure sex-matched comparisons for this female-specific disorder, all iPSC lines were derived from female donors with confirmed 46,XX karyotypes. Each line exhibited characteristic iPSC morphology and validated pluripotency, with the capacity to differentiate into all three germ layers confirmed through in vitro and in vivo assays. The establishment of iPSCs was approved by the Research Ethics Committee of the National Taiwan University Hospital (No: 200907056R), and all participants provided informed consent.
Patients were diagnosed with PCOS based on the Rotterdam criteria.39 All iPSC donors were of Han Chinese ethnicity. The age and demographic characteristics of the three PCOS and three control women are provided in Table S2. The P7 iPSC line was authenticated by STR profiling as previously described.41 While the other iPSC lines were not authenticated by STR profiling, all cell lines used in this study were strictly characterized by karyotype analysis.
Furthermore, all cell lines were routinely tested for mycoplasma contamination and confirmed to be negative. iPSCs culture and maintenance were modified from established protocols.42 In brief, iPSCs were maintained on Mouse embryonic fibroblasts (MEF feeder cells) (iXcells Biotechnologies, San Diego, CA, USA) in serum-free Primate ES Cell Medium (ReproCELL ES cell medium, Kanagawa, Japan) supplemented with 10 ng/mL basic fibroblast growth factor (bFGF) (R&D Systems, Minneapolis, MN, USA) in a humidified incubator under 5% CO2 at 37°C. The medium was changed daily. Cells were split weekly using 30-gauge insulin needles (Terumo Syringe, Tokyo, Japan) as previously described.
Endothelial cellular differentiation protocols were adapted from our previous study.43 iPSCs were manually split into small clumps and plated onto human embryonic stem cell-qualified Matrigel (Corning Inc., Corning, NY, USA)-coated 6-well plates in MEF-conditioned medium with an additional 10 ng/mL bFGF (R&D Systems, Minneapolis, MN, USA). On day 0, the cells were treated with 6 μM CHIR99021 (Tocris Bioscience, Avonmouth, UK) in StemDiff APEL medium (STEMCELL Technologies, Vancouver, BC, Canada). After three days, 25 ng/mL bone morphogenetic protein 4 (BMP4) (R&D Systems, Minneapolis, MN, USA), 10 ng/mL bFGF (R&D Systems, Minneapolis, MN, USA), and 50 ng/mL vascular endothelial growth factor (VEGF) (R&D Systems, Minneapolis, MN, USA) were added to StemDiff APEL medium for two days.
The cells were then dissociated with Accutase (Thermo Scientific, Waltham, MA, USA) and seeded onto 1% gelatin-coated cell culture dishes in EC growth medium MV2 (ECGM-MV2, PromoCell, Heidelberg, Germany) supplemented with 50 ng/mL VEGF (R&D Systems, Minneapolis, MN, USA). ECGM-MV2 was changed every two days for EC generation. The ECs were split every 4-6 days.
ECs used in this experiment were at passage 2 to 5. Our previous study demonstrated that CD31+CD144+ double-positive ECs were generated from PCOS and control iPSCs with high differentiation efficiency (up to 90%).43 These iPSC-ECs expressed the mature EC marker von Willebrand factor (vWF) and demonstrated comparable abilities for LDL uptake and tube formation on Matrigel. Confluent ECs were seeded in multi-well plates and exposed for 24 hours to NG (5.5 mM), HG (30 mM glucose), or an osmotic medium consisting of NG supplemented with 24.5 mM mannitol.
In specific experiments evaluating MPO activity, cells were pre-treated with 4-ABAH (50 μM) (Cayman Chemical, MI, USA) for 1 hour, followed by co-incubation with HG for 24 hours. All treatment media were prepared by diluting ECGM-MV2 (PromoCell, Heidelberg, Germany) 1:5 with endothelial basal medium (ECBM-MV2) (PromoCell, Heidelberg, Germany).
Study subjects
This study was conducted with 20 age- and BMI-matched Han Chinese control women without PCOS (age 28.3 ± 4.1 years; BMI 29.2 ± 2.7 kg/m2) and 22 Han Chinese women with PCOS (age 26.9 ± 4.2 years; BMI 30.5 ± 2.6 kg/m2) at the National Taiwan University Hospital. The study was approved by the Ethics Committee of the National Taiwan University Hospital (No: 201810116RINC). The diagnosis of PCOS adhered to the Rotterdam criteria, requiring the presence of at least two of the following: (1) clinical (hirsutism and alopecia) and/or biochemical hyperandrogenism (HA) (serum total testosterone level ≥ 0.8 ng/mL ); (2) amenorrhea or oligomenorrhea (fewer than 9 spontaneous menstrual cycles per year for at least 3 years before enrollment); and (3) PCOM on ultrasonography (> twelve 2-9 mm follicles or an ovarian volume > 10 ml in at least 1 ovary).39 All participants were treatment-naïve at the time of blood sampling and clinical evaluation.
Exclusion criteria included hyperprolactinemia, thyroid dysfunction, Cushing syndrome, congenital adrenal hyperplasia, adrenal tumors, or other virilizing ovarian tumors.
Method details
Tube formation assay
After an 18-hour pre-incubation in NG, HG, HG plus 4-ABAH (50 μM) (Cayman Chemical, MI, USA), or mannitol medium, approximately 1.5 x 104 cells per well were harvested and re-seeded onto 96-well plates coated with growth factor-reduced Matrigel (Corning Inc., Corning, NY, USA) for an additional 6 hours under the respective conditions. Images were taken at 40x magnification using an inverted microscope (ECLIPSE TE2000-U). The total tube length was quantified using the Angiogenesis Analyzer, a Fiji plugin for the Mac OS X version of ImageJ.
Mitochondrial network analysis
iPSC-ECs were seeded at 3 x 104 cells/well in 4-well glass chamber slides coated with 1% gelatin and cultured to 60% confluence. After 24-hour treatment with NG or HG, cells were fixed and permeabilized with 4% Paraformaldehyde (PFA) and 0.3% Triton X-100 (Merck KGaA, Darmstadt, Germany). Mouse anti-TOM20 (Santa Cruz, CA, USA) was used at a 1:100 dilution, and the secondary antibody, Alexa Fluor 488 rabbit anti-mouse (Abcam, Cambridge, MA, UK), was used at a 1:500 dilution.
Hoechst 33342 (Corning Inc., Corning, NY, USA) was used for nuclei staining (blue). Images were acquired via Leica SP8 confocal microscope using a 63x oil immersion objective and analyzed using the ImageJ tool MiNA to quantify mitochondrial footprint, mean branch length and number of branches.44
RNA extraction, cDNA preparation, and quantitative PCR
Total RNA was harvested using TRIzol reagent (Invitrogen, Waltham, MA, USA), following the manufacturer’s instructions. Reverse transcription was performed using a Maxima First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). 2 μg of total RNA was used to synthesize cDNA for each sample.
Quantitative PCR (qPCR) was performed with the Fast SYBR Green Master Mix (Thermo Scientific, Waltham, MA, USA) on the Applied Biosystems StepOne Plus system (Applied Biosystems, Carlsbad, CA, USA). The qPCR procedure began with a 2-min incubation at 95°C, followed by 40 cycles of 15 s at 95°C, 30 s at 55°C, and 30 s at 72°C. Target gene expression levels were calibrated using Eukaryotic Translation Elongation Factor 1 Alpha 1 (eEF1α1), and data were analyzed using the ABI 7500 Fast Real-Time PCR system.
Quantification was calculated from the cycle threshold (CT), and relative fold changes were calculated using the 2-ΔΔCT method.
Western blot analysis
1-1.5 x 107 Cells were lysed in RIPA Lysis buffer (Millipore, Billerica, MA, USA) supplemented with Halt Protease and Phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA, USA). Western blot analysis was performed as previously described.43 Protein concentration was determined using the Pierce BCA Protein Assay kit (Thermo Scientific, Waltham, MA, USA). Samples containing 30 μg of total protein were separated by electrophoresis on a 12% SDS-polyacrylamide gel and transferred to PVDF membranes (Millipore, Billerica, MA, USA).
All primary antibody incubations were performed overnight at 4°C with the following dilutions: rabbit anti-MFN1 (Cell Signaling Technology, Danvers, MA, USA), 1:1000; rabbit anti-MFN2 (Cell Signaling Technology, Danvers, MA, USA), 1:1000; rabbit anti-OPA1 (Cell Signaling Technology, Danvers, MA, USA), 1:1000; rabbit anti-DRP1 (Cell Signaling Technology, Danvers, MA, USA), 1:1000; rabbit anti-FIS1 (Santa Cruz, CA, USA), 1:1000; rabbit anti-MPO (Cell Signaling Technology, Danvers, MA, USA), 1:1000; goat anti-β-Actin (Abcam, Cambridge, MA, UK), 1:500. After secondary antibody reaction, the signal was detected using ECL (Thermo Scientific, Waltham, MA, USA). Band signals on the blots were measured with ImageJ.
Relative protein expression levels were determined by the density ratio of the target protein to the housekeeping protein and normalized to the control.
Measurement of mitochondrial ROS
Mitochondrial ROS was measured using the MitoSOXTM dye (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Briefly, cells were seeded in 96-well plates in NG, HG, HG plus 4-ABAH, or mannitol conditions for 24 hours, washed with PBS, and then incubated with 5 μM MitoSOXTM for 30 min. Fluorescence was quantified using a microplate fluorescence reader (Fluoroskan ASCENT, Thermo Fisher Scientific Japan) using 10 ng/mL IL-1β (R&D Systems, Minneapolis, MN, USA) as a positive control and 100 μM DETA NONOate (Sigma-Aldrich, Missouri, USA) as a negative control.
Bioenergetics analysis
Mitochondrial respiration and energy production in iPSC-ECs were measured using the Seahorse XFe24 extracellular flux analyzer and analyzed by Seahorse XFe24 wave software version Wave 2.2 (Agilent, Santa Clara, CA, USA). Cells were plated in a Seahorse microplate at a density of 4 x 104 cells/well overnight and treated with NG or HG for 24 hours. OCRs were assessed following sequential injections of oligomycin (0.5 μM; ATP synthase inhibitor), Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) (1 μM; mitochondrial uncoupler), and rotenone/antimycin A (0.5 μM; mitochondrial complex I and III inhibitors, respectively) using the Seahorse XF Cell Mito Stress Test Kit (Agilent, Santa Clara, CA, USA) to determine basal respiration, maximal respiration, ATP production, and spare respiratory capacity.
OCRs were normalized to the total cell count.
Measurement of serum MPO levels
Overnight fasting blood samples were collected from women with PCOS and control subjects. Serum MPO concentrations were measured using a Quantikine enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Bio-Techne Ltd, Abingdon, UK), according to the manufacturer’s instructions.
Quantification and statistical analysis
Statistical analyses for experimental data were performed using GraphPad Prism 10, and data are presented as mean ± standard deviation (SD). The sample size (n) was defined as the total number of independent experimental runs (differentiation batches). Specifically, n = 9 per group, comprising three independent runs performed on each of the three distinct donor-derived iPSC lines per group.
Data from these nine independent runs were pooled for statistical analysis. Comparisons were analyzed using two-way ANOVA to evaluate the effects of varying conditions within each respective group (control and PCOS). For experiments comparing NG and HG only, Sidak’s multiple comparisons test was utilized to determine significant differences between these conditions within each group.
For experiments involving multiple conditions (HG, IL-1β, and inhibitor), Dunnett’s multiple comparisons test was applied to compare each condition against the NG control within the control or PCOS groups, respectively. For experiments involving multiple MPO inhibition and osmotic treatments (HG plus 4-ABAH and mannitol), statistical differences among conditions within the respective control or PCOS cohorts were assessed using Tukey’s multiple comparisons test. Statistical analyses of clinical data were performed using R software (version 4.3.3) and R Studio (version 2024.04.2).
Differences in clinical and biochemical characteristics between women with PCOS and controls were assessed using an unpaired Student’s t-test for continuous variables and a Chi-squared test for categorical variables. Categorical variables were compared using the Pearson Chi-squared test, or Fisher’s exact test when expected cell counts were less than five. Pearson’s correlation analysis was employed to determine the associations between circulating MPO levels and clinical metabolic characteristics.
Multiple linear regression with a group-by-MPO interaction term was used to analyze clinical data. All plots were generated using the ggplot2 R package (version 3.5.1). Multivariable linear regression models were constructed to assess the association between serum MPO and glucose levels.
The models were sequentially adjusted for potential clinical confounders, including BMI, insulin, and blood pressure parameters as indicated to evaluate their independent relationships. In all cases, a p-value < 0.05 was considered statistically significant.